{"id":20366,"date":"2026-06-11T01:14:16","date_gmt":"2026-06-11T01:14:16","guid":{"rendered":"https:\/\/www.europesays.com\/be\/20366\/"},"modified":"2026-06-11T01:14:16","modified_gmt":"2026-06-11T01:14:16","slug":"i-senss-continuous-glucose-monitor-listed-for-belgium-public-insurance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/be\/20366\/","title":{"rendered":"i-SENS\u2019s Continuous Glucose Monitor Listed for Belgium Public Insurance"},"content":{"rendered":"

i-SENS\u2019s continuous glucose monitoring (CGM) device, \u201cCareSens Air,\u201d has been included in the list of diabetes convention reimbursed devices by Belgium\u2019s National Institute for Health and Disability Insurance (INAMI).<\/p>\n

\t
\n\t\t\t
\n\t\t\t\t\"i-SENS\u2019s
\n\t\t\t<\/a><\/p>\n

\t\t\t
\n\t\t\t\tView original image
\n\t\t\t<\/a><\/p>\n

According to i-SENS on June 11, the diabetes convention is a management program operated based on agreements signed between INAMI and hospitals. Hospitals recognized as diabetes convention centers receive comprehensive budget support from INAMI and provide diabetes management services\u2014such as CGM devices\u2014to registered patients. Through this inclusion, CareSens Air has been officially recognized as a reimbursable device within the Belgian insurance channel, establishing a practical foundation for sales in Belgium.<\/p>\n

In the first quarter of this year, i-SENS recorded CGM sales of approximately 8.4 billion won, marking a 172% increase from the same period last year and achieving the company\u2019s highest-ever quarterly result. Following its additional listing under public health insurance in Germany (GKV) and the UK (NHS) this April, the completion of the Belgian listing has further expanded the scope of countries in Europe offering insurance reimbursement, providing additional growth momentum for overseas CGM sales.<\/p>\n

i-SENS is continuing to pursue insurance reimbursement listings in major countries and plans to launch in more than nine new countries this year, accelerating the global expansion of its CGM business. Including the recent listing in Belgium, CareSens Air is now reimbursed in ten countries: South Korea, the United Kingdom, Estonia, Hungary, Poland, Czech Republic, Croatia, Israel, Germany, and Belgium.<\/p>\n

<\/p>\n

Hot Picks Today
\n
\n \""The
\n “The Sooner You Start, the Better: Millennials & Gen Z Should Gradually Move Stock Gains ‘Here’ [Retirement Pension Investment Strategy] \u2467”
\n <\/a><\/p>\n

An i-SENS representative stated, \u201cThe inclusion in Belgium\u2019s INAMI is another significant milestone in expanding CGM insurance reimbursement coverage across Europe,\u201d adding, \u201cWe will continue to work on expanding global insurance reimbursement and deepening market penetration to achieve this year\u2019s CGM sales target of 40 billion won.\u201d<\/p>\n

<\/p>\n

This content was produced with the assistance of AI translation services.<\/p>\n

\u00a9 The Asia Business Daily(www.asiae.co.kr). All rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"i-SENS\u2019s continuous glucose monitoring (CGM) device, \u201cCareSens Air,\u201d has been included in the list of diabetes convention reimbursed…\n","protected":false},"author":2,"featured_media":20367,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[7,4713,10356,10357,144,930,192,5290,5383,10355],"class_list":["post-20366","post","type-post","status-publish","format-standard","has-post-thumbnail","category-belgium","tag-belgium","tag-economic","tag-issue","tag-korea","tag-news","tag-newspaper","tag-politics","tag-society","tag-south-korea","tag-the-asia-business-daily"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@be\/116728828020253591","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/20366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/comments?post=20366"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/posts\/20366\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media\/20367"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/media?parent=20366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/categories?post=20366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/be\/wp-json\/wp\/v2\/tags?post=20366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}